ArticleScientific reports2025
Intraarterial microbubble delivery enhances focused ultrasound induced blood brain barrier opening in the murine substantia nigra.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Focused ultrasound for cellular mechanoactivation and nanomedicine delivery in cancer.Biomedical microdevices · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Focused ultrasound (FUS) combined with microbubbles facilitates blood-brain barrier (BBB) opening to enhance therapeutic delivery to the substantia nigra for Parkinson's disease treatment. While intravenous (IV) microbubble administration is commonly used, the efficacy of intra-arterial (IA) delivery remains unclear. This study compared IA versus IV administration of low (2.80 × 10⁸/kg) and high (1.12 × 10⁹/kg) microbubble doses for FUS-induced BBB opening in the murine substantia nigra. FUS was applied at a BBB-opening threshold (mechanical index: 0.42; 1 Hz; 60 s; 1% duty cycle; bregma - 3.16 mm). BBB permeability was assessed using Evans blue (EB) dye extravasation and IgG immunohistochemistry. EB staining of peripheral organs evaluated systemic off-target effects. At the low dose, Near-Infrared Fluorescence imaging on the LI-COR Odyssey system showed lower EB signals in the stomach and liver (both P = 0.01) in the IA group versus the IV low-dose MB group. Notably, high-dose IA administration led to greater IgG extravasation in deep brain regions, including thalamus (P = 0.002) and substantia nigra (P = 0.0001), and reduced off-target effects in the stomach (P = 0.004), lung (P = 0.04), liver (P = 0.004), and spleen (P = 0.02) compared to the IV high-dose group. IA delivery offers enhanced BBB opening but requires safety considerations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.